NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to Mild Cognitive Impairment.

NPTX2 may be a valuable prognostic biomarker during preclinical AD that provides additive and independent prediction of MCI onset among individuals who are cognitively normal. We hypothesize that NPTX2-mediated circuit homeostasis confers resilience during the early phase of AD. This article is protected by copyright. All rights reserved.